120
Views
3
CrossRef citations to date
0
Altmetric
Theme: Diabetes - Review

Treatment of hypertension in diabetes: a contemporary approach with a focus on improving cardiovascular outcomes

, &

References

  • Centers for Disease Control and Prevention. National diabetes statistics report: estimates of diabetes and its burden in the United States, 2014. Atlanta (GA): U.S. Department of Health and Human Services; 2014.
  • American Diabetes Association. Chapter 8. Cardiovascular disease and risk management. Diabetes Care. 2015;38:S49–S57.
  • Karuparthi PR, Yerram P, Lastra G, et al. Understanding essential hypertension from the perspective of the cardiometabolic syndrome. J Am Soc Hypertens. 2007;1(2):120–134.
  • Ogden CL, Carroll MD, Kit BK, et al. Prevalence of obesity among adults: United States, 2011–2012. NCHS data brief, no 131. Hyattsville (MD): National Center for Health Statistics; 2013.
  • Kurukulasuriya LR, Stas S, Lastra G, et al. Hypertension in obesity. Med Clin North Am. 2011;95:903–917.
  • Sowers JR, Whaley-Connell A, Epstein M. Narrative review: the emerging clinical implications of the role of aldosterone in the metabolic syndrome and resistant hypetension. Ann Intern Med. 2009;150(11):776–783.
  • Williams B. The hypertension in diabetes study (HDS): a catalyst for change. Diabet Med. 2008;25(Suppl. 2):13–19.
  • Lastra G, Syed S, Kurukulasuriya LR, et al. Type 2 diabetes mellitus and hypertension: an update. Endocrinol Metab Clin North Am. 2014;43(1):103–122.
  • DeMarco VG, Habibi J, Jia G, et al. Low-dose mineralocorticoid receptor blockade prevents western diet-induced arterial stiffening in female mice. Hypertension. 2015;66(1):99–107.
  • Frontoni S, Solini A, Fioretto P, et al. The ideal blood pressure target to prevent cardiovascular disease in type 2 diabetes: a neutral viewoint. Nutr Metab Cardiovas Dis. 2014;24:577–584.
  • Sowers JR. Recent advances in hypertension. J Am Heart Assoc. 2013;61:943–947.
  • James PA, Oparil S, Carter BL, et al. 2014 evidence-based guideline for the management of high blood pressure in adults: report from the panel members appointed to the eighth joint national committee (JNC 8). JAMA. 2014;311(5):507–520.
  • The ACCORD study group. Effects of intensive blood pressure control in patients with type 2 diabetes. N Eng J Med. 2010;362:1575–1585.
  • Pepine CJ, Handberg EM, Cooper-DeHoff RM, et al., for the INVEST Investigators. A calcium antagonist vs a non–calcium antagonist hypertension treatment strategy for patients with coronary artery disease: the international verapamil-trandolapril study (INVEST): a randomized controlled trial. JAMA. 2003;290(21):2805–2816.
  • The ONTARGET Investigators. Telmisartan, Ramipril, or both in patients at high risk for vascular events. N Eng J Med. 2008;358:1547–1559.
  • Duckworth W, Abraira C, Moritz T, et al. VADT Investigators. Glucose control and vascular complications in veterans with type 2 diabetes. N Engl J Med. 2009;360:129–139.
  • Handelsman Y, Bloomgarden ZT, Grunberger G, et al. American Association of Clinical Endocrinologists and American College of Endocrinology - clinical practice guidelines for developing a diabetes mellitus comprehensive care plan - 2015. Endocr Pract. 2015;21(4):413–437.
  • Mancia G, Fagard R, Narkiewicz K, et al. 2013 ESH/ESC guidelines for management of arterial hypertension. Eur Heart J. 2013;34:2159–2219.
  • Dasgupta K, Quinn RR, Zarnke KB, et al. The 2014 canadian hypertension education program recommendations for blood pressure measurement, diagnosis, assessment of risk, prevention, and treatment of hypertension. Can J Cardiol. 2014;30(5):485–501.
  • Blumenthal JA, Babyak MA, Hinderliter A, et al. Effects of the DASH diet alone and in combination with exercise and weight loss on blood pressure and cardiovascular biomarkers in men and women with high blood pressure: the ENCORE study. Arch Intern Med. 2010;170(2):126–135.
  • Look AHEAD Research Group. Reduction in weight and cardiovascular disease risk factors in individuals with type 2 diabetes: one-year results of the look AHEAD trial. Diabetes Care. 2007;30(6):1374–1383.
  • The Look AHEAD Research Group. Cardiovascular effects of intensive lifestyle intervention in type 2 diabetes. N Engl J Med. 2013;369:145–154.
  • Sussman JB, Kent DM, Nelson JP, et al. Improving diabetes prevention with benefit based tailored treatment: risk based reanalysis of diabetes prevention program. BMJ. 2015;350:h454.
  • Mistry GC, Maes AL, Lasseter KC, et al. Effect of sitagliptin, a dipeptidyl peptidase-4 inhibitor, on blood pressure in nondiabetic patients with mild to moderate hypertension. J Clin Pharmacol. 2008;48:592–598.
  • Bergenstal R, Kim T, Trautmann M, et al. Exenatide once weekly elicited improvements in blood pressure and lipid profile over 52 weeks in patients with type 2 diabetes (abstract no. 1239). Circulation. 2008;118:S1086.
  • Kurukulasuriya LR, Sowers JR. Therapies for type 2 diabetes: lowering HbA1c and associated cardiovascular risk factors. Cardiovasc Diabetol. 2010;9:45.
  • Green JB, Bethel MA, Armstrong PW, et al., for the TECOS Study Group. Effect of sitagliptin on cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2015;373:232–242.
  • Aroor AR, Sowers JR, Jia G, et al. Pleiotropic effecs of the dipeptidylpeptidase-4 inhibitors on the cardiovascular system. Am J Physiol Heart Circ Physiol. 2014;307:H477–H492.
  • UK Prospective Diabetes Study Group. Effect of intensive blood glucose control with metformin on complications in overweight patients with type 2 diabetes: UKPDS 34. Lancet. 1998;352:854–865.
  • Vijakama P, Thakkinstian A, Lertrattananon D, et al. Reno-protective effects of renin-angiotensin system blockade in type 2 diabetic patients: a systematic review and network meta-analysis. Diabetologia. 2012;55:566–578.
  • Wu HY, Huang JW, Lin HJ, et al. Comparative effectiveness of renin-angiotensin system blockers and other antihypertensive drugs in patients with diabetes: systematic review and bayesian network meta-analysis. Bmj. 2013;347:f6008.
  • Grossman E, Messerli FH. Management of blood pressure in patients with diabetes. Am J Hypertens. 2011;24(8):863–875.
  • Jeffers BW, Bhambri R, Robbins J. Uptitrating amlodipine significantly reduces blood pressure in diabetic patients with hypertension: a retrospective, pooled analysis. Vasc Health Risk Manag. 2014;10:651–659.
  • Reboldi G, Gentile G, Angeli F, et al. Optimal therapy in hypertensive subjects with diabetes mellitus. Curr Atheroscler Rep. 2011;13:176–185.
  • Williams B, MacDonald TM, Morant S, et al., for The British Hypertension Society’s PATHWAY Studies Group. Spironolactone versus placebo, bisoprolol, and doxazosin to determine the optimal treatment for drug-resistant hypertension (PATHWAY-2): a randomised, double-blind, crossover trial. Lancet. 2015. DOI:10.1016/S0140-6736(15)00257-3.
  • Sowers JR, Lastra G, Rocha R, et al. Initial combination therapy compared with monotherapy in diabetic hypertensive patients. J Clin Hypertens (Greenwich). 2008;10:668–676.
  • Kanda T, Wakino S, Hayashi K, et al. Cardiovascular disease, chronic kidney disease, and type 2 diabetes mellitus: proceeding with caution at a dangerous intersection. J Am Soc Nephrol. 2008;19:4–7.
  • Schiffrin EL, Lipman ML, Mann JF. Chronic kidney disease: effects on the cardiovascular system. Circulation. 2007;116:85–97.
  • Zinman B, Wanner C, Lachin JM, et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. NEJM. 2015;373:2117–2128.
  • The SPRINT Research group. A randomized trial of intensive vs standard blood pressure control. NEJM. 2015;373:2103–2116.
  • Perez-Pozo SE, Schold J, Nakagawa T, et al. Excessive fructose intake induces the features of metabolic syndrome in healthy adult men: role of uric acid in the hypertensive response. Int J Obes (Lond). 2010;34:454–461.
  • Jia G, Habibi J, Bostick BP, et al. Uric acid promotes left ventricular diastolic dysfunction in mice fed a western diet. Hypertension. 2015;65(3):531–539.
  • DeMarco VG, Sowers JR. Ghrelin: a new incretin enhancer therapy? Diabetes. 2015;64:1500–1502.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.